Peptide-based probes for cancer imaging

260Citations
Citations of this article
153Readers
Mendeley users who have this article in their library.

Abstract

Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include second- and third-generation somatostatin analogs, with a broader receptor subtype profile or with antagonistic properties. Emerging tracers for other peptide receptors, including cholecystokinin/gastrin and GLP-1 analogs for neuroendocrine tumors, bombesin and neuropeptide-Y analogs for prostate or breast cancers, or Arg-Gly-Asp peptides for neoangiogenesis labeling, are also in current development. Application fields include both SPECT/CT and PET/CT. Copyright © 2008 by the Society of Nuclear Medicine, Inc.

Cite

CITATION STYLE

APA

Reubi, J. C., & Maecke, H. R. (2008, November 1). Peptide-based probes for cancer imaging. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.108.053041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free